Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Tango Therapeutics, Inc.

NASDAQ: TNGX · Life Sciences · 8 alerts · CIK 1819133

Share price
$24.17Close, Nov 16
Market cap
$4.1B
Shares outstanding
169.46MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Tango Therapeutics, Inc. filings on SEC EDGAR ↗

7:14 AM ET 8-K
Financial Results

Tango Therapeutics Financial Results

Tango Therapeutics reported third quarter 2026 financial results, highlighting a strong cash position of $977.5 million. The company announced plans to initiate a pivotal Phase 3 study of vopimetostat plus daraxonrasib for front-line pancreatic cancer in the first half of 2027 following positive Phase 1/2 data.

“In 2026, Tango has made significant strides towards bringing vopimetostat to patients with pancreatic cancer. This progress is rooted first in the data. Last month at ESMO, we shared promising data from the combination of vopimetostat plus daraxonrasib that reinforced the potential of this program to raise the bar for patients with MTAP-deleted and RAS-mutant pancreatic cancer.”

Malte Peters, MD, President and Chief Executive Officer of Tango
7:12 AM ET 10-Q
Financial Results

Tango Therapeutics Q3 2026 Results: Net Loss of $68.4M

Tango Therapeutics is a precision oncology company that remains in the clinical development stage with no approved products or revenue from sales. As of November 2, 2026, the company had 169,455,160 shares of common stock outstanding and continues to anticipate significant net losses as it advances its clinical programs, including a planned registrational trial for vopimetostat in 2027.

Key figure
Net loss $68.4M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.